StockNews.AI
PRAX
StockNews.AI
6 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

1. Pomerantz LLP is investigating potential securities fraud by Praxis. 2. Praxis reported mid-stage adverse results for vormatrigine, shocking investors. 3. Stock price dropped 5.55% on negative study outcomes and investigation announcement. 4. 36 of 61 patients faced treatment-emergent adverse events. 5. Stock closed at $51.09 after adverse press release on August 4.

3m saved
Insight
Article

FAQ

Why Bearish?

Negative mid-study results and ongoing investigation may deter investors. Historical examples show similar stock declines in biotech sectors under scrutiny.

How important is it?

Investor sentiment is important following negative news and investigations, impacting stock valuation.

Why Short Term?

The immediate fallout from the investigation and study results will likely affect stock performance in the short term.

Related Companies

CBAYAKTXNVAX
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025.  Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine.  The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study.  On this news, Praxis’s stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News